1. Home
  2. LQDA vs ASIC Comparison

LQDA vs ASIC Comparison

Compare LQDA & ASIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LQDA
  • ASIC
  • Stock Information
  • Founded
  • LQDA 2004
  • ASIC 2018
  • Country
  • LQDA United States
  • ASIC United States
  • Employees
  • LQDA N/A
  • ASIC N/A
  • Industry
  • LQDA Biotechnology: Pharmaceutical Preparations
  • ASIC Property-Casualty Insurers
  • Sector
  • LQDA Health Care
  • ASIC Finance
  • Exchange
  • LQDA Nasdaq
  • ASIC Nasdaq
  • Market Cap
  • LQDA 1.3B
  • ASIC 1.2B
  • IPO Year
  • LQDA 2018
  • ASIC 2025
  • Fundamental
  • Price
  • LQDA $13.17
  • ASIC $22.76
  • Analyst Decision
  • LQDA Strong Buy
  • ASIC
  • Analyst Count
  • LQDA 9
  • ASIC 0
  • Target Price
  • LQDA $27.67
  • ASIC N/A
  • AVG Volume (30 Days)
  • LQDA 3.0M
  • ASIC 550.0K
  • Earning Date
  • LQDA 08-06-2025
  • ASIC 01-01-0001
  • Dividend Yield
  • LQDA N/A
  • ASIC N/A
  • EPS Growth
  • LQDA N/A
  • ASIC N/A
  • EPS
  • LQDA N/A
  • ASIC 0.12
  • Revenue
  • LQDA $14,144,000.00
  • ASIC $350,888,000.00
  • Revenue This Year
  • LQDA $185.38
  • ASIC N/A
  • Revenue Next Year
  • LQDA $350.95
  • ASIC N/A
  • P/E Ratio
  • LQDA N/A
  • ASIC $198.15
  • Revenue Growth
  • LQDA N/A
  • ASIC 42.48
  • 52 Week Low
  • LQDA $8.26
  • ASIC $22.00
  • 52 Week High
  • LQDA $19.41
  • ASIC $25.30
  • Technical
  • Relative Strength Index (RSI)
  • LQDA 36.80
  • ASIC N/A
  • Support Level
  • LQDA $13.60
  • ASIC N/A
  • Resistance Level
  • LQDA $14.63
  • ASIC N/A
  • Average True Range (ATR)
  • LQDA 0.96
  • ASIC 0.00
  • MACD
  • LQDA -0.40
  • ASIC 0.00
  • Stochastic Oscillator
  • LQDA 0.46
  • ASIC 0.00

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

About ASIC Ategrity Specialty Insurance Company Holdings Common Stock

Ategrity Specialty Insurance Co Holdings Formerly Ategrity Specialty Holdings LLC is a specialty insurance company dedicated to providing excess and surplus products to small to medium-sized businesses across the United States. It offers property and casualty insurance solutions tailored to meet the needs of SMBs. The company focuses on are Real Estate, Hospitality, Construction, and Retail.

Share on Social Networks: